Seeking Alpha
 

Raptor Pharmaceutical Corp. (RPTP)

- NASDAQ
  • Thu, Feb. 26, 4:08 PM
    • Raptor Pharmaceutical (NASDAQ:RPTP): Q4 EPS of -$0.25 misses by $0.11.
    • Revenue of $17.3M (+68.8% Y/Y) misses by $2.82M.
    • Shares -1.1%.
    • Press Release
    | Comment!
  • Nov. 6, 2014, 5:29 PM
    • Raptor Pharmaceutical (NASDAQ:RPTP): Q3 EPS of -$0.10.
    • Non - Gaap EPS of -$0.04.
    • Revenue of $23.76M (+260.0% Y/Y) beats by $4.84M.
    • Press Release
    | Comment!
  • Aug. 8, 2014, 3:49 PM
    • First the good news:
    • Tekmira (TKMR +38.1%) on a massive 25M share turnover; Raptor Pharmaceuticals (RPTP +28.2%) on a 4x surge in volume; Clovis Oncology (CLVS +11.6%) on 50% higher volume; RadNet (RDNT +20.4%) on 2x higher volume and Relypsa (RLYP +15%) on 2x higher volume.
    • Now the bad news:
    • TearLab (TEAR -21.2%) on 4x higher volume; Masimo (MASI -10.6%) on 3x higher volume; Volcano (VOLC -19.9%) on a 12x surge in volume and Hanger (HGR -24.9%) on a 16x surge in volume.
    | 1 Comment
  • Aug. 8, 2014, 9:45 AM
    • Raptor Pharmaceuticals (RPTP +19.7%) Q2 results: Net Product Sales: $16.3M (-22.4%); Operating Expenses: $24.4M (+56.4%); Operating Loss: ($9.1M) (+43.1%); Net Loss: ($12.7M) (+47.3%); Loss Per Share: ($0.20) (+53.5%); Quick Assets: $58.1M (-30.0%).
    • 2014 Guidance: Net product sales: $65M - 70M from $55M - 65M; non-GAAP operating expenses: $80M - 90M; quick assets will be sufficient to fund operations through at least 1H 2016.
    | Comment!
  • Aug. 7, 2014, 4:18 PM
    • Raptor Pharmaceutical (NASDAQ:RPTP): Q2 EPS of -$0.15 beats by $0.06.
    • Revenue of $16.31M beats by $1.73M.
    • Press Release
    | Comment!
  • May. 8, 2014, 4:35 PM
    • Raptor Pharmaceutical (RPTP): Q1 EPS of -$0.20 misses by $0.02.
    • Revenue of $12.1M beats by $0.29M.
    • Press Release
    | Comment!
  • Mar. 13, 2014, 5:02 PM
    • Raptor Pharmaceutical (RPTP): Q4 EPS of -$0.19 misses by $0.03.
    • Revenue of $10.25M beats by $1.23M.
    • Press Release
    | Comment!
  • Aug. 9, 2013, 8:50 AM
    • Raptor Pharmaceuticals (RPTP): Q2 EPS of -$0.30 in-line.
    • Revenue of $21K misses by $9.K. (PR)
    | Comment!
  • May. 9, 2013, 11:52 AM
    Raptor Pharmaceuticals (RPTP): Q1 EPS of $-0.30. (PR)
    | Comment!
  • Mar. 14, 2013, 4:55 PM
    Raptor Pharmaceuticals (RPTP): Q4 EPS of -$0.37 misses by $0.10. (PR)
    | 1 Comment
  • Mar. 14, 2013, 4:40 PM
    More on Raptor Pharmaceutical (RPTP): Q4 EPS misses estimates by a large margin, and are down 28% from the same quarter last year. R&D expenses increased nearly 50% to $9M, driven largely by higher product manufacturing costs for RP103, its treatment for cystinosis, Huntington's disease and non-alcoholic steatohepatitis, plus other supporting study expenses and employee compensation. SG&A costs also ramped up during the quarter due to marketing expenses attributed to RP103 as well.
    | Comment!
  • Jan. 9, 2013, 4:13 PM
    Raptor Pharmaceutical (RPTP): FQ1 EPS of -$0.26 misses by $0.03. (PR)
    | Comment!
Visit Seeking Alpha's
RPTP vs. ETF Alternatives
Company Description
Raptor Pharmaceutical Corp is abiopharmaceuticalcompany. It is engaged indeveloping and commercializing transformative treatments for people affected by rare and debilitating diseases.